Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Neuroblastoma 1

Interventions

Specimen Handling 134pembrolizumab 123Magnetic Resonance Spectroscopy 112Carboplatin 88Cyclophosphamide 82Biopsy 75Cisplatin 61Bevacizumab 59Paclitaxel 58Gemcitabine 57Nivolumab 53fludarabine 46Rituximab 41atezolizumab 39Pemetrexed 38Fluorouracil 38Docetaxel 38Dexamethasone 38Doxorubicin 35Radiotherapy 33Leucovorin 33Capecitabine 33venetoclax 32Prednisone 32Oxaliplatin 31Temozolomide 30130-nm albumin-bound paclitaxel 29Standard of Care 27Cetuximab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × 3-Iodobenzylguanidine × 30 days × Clear all
NCT00107289 2026-05-29

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
200 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡